The problem. By 2000, cancer research was drowning in molecular detail — hundreds of oncogenes and tumor suppressors, thousands of mutations — with no organizing framework. Every tumor looked different. Was there any common logic beneath the mess?

The idea. Hanahan and Weinberg proposed that the bewildering variety of cancers can be understood as a small set of acquired capabilities — sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. Any tumor, however it gets there genetically, has to solve the same handful of problems. The hallmarks are functional endpoints, not specific mutations — a rule set, not a parts list.

Why it matters. This is the framework I read tumor data through. My AML RNA-seq work — differential expression between leukemic and normal samples — is ultimately asking which hallmarks are engaged and how. And the spatial and single-cell methods I’ve been reading exist largely to dissect exactly this in tissue. Having a shared conceptual map is what lets a result become a story rather than a gene list.

Verdict. Foundational and unusually durable — a review that shaped how a field thinks, later extended (2011, 2022) with new hallmarks like altered metabolism and immune evasion. Its risk is that a clean framework can flatten real heterogeneity, so I read it as a lens, not a checklist. Essential orientation for anyone working near oncology.